Understanding Tumor Mutational Burden in Immunotherapy |…

What is Tumor Mutational Burden?

Tumor mutational burden (TMB) refers to the total number of somatic mutations present in a tumor’s genome. High TMB indicates a higher rate of genetic alterations, which can lead to more neoantigens—new proteins that the immune system may recognize as foreign and target. This concept is pivotal in precision oncology, where understanding the genomic landscape of tumors helps tailor treatment strategies.

TMB is measured by sequencing the tumor DNA and comparing it with a reference genome, identifying all mutations present. The TMB score is then calculated based on the number of unique mutations per megabase (Mb) of sequenced DNA.

How Does Tumor Mutational Burden Relate to Immunotherapy?

Immunotherapy, particularly immune checkpoint inhibitors, works by unleashing the body’s immune system against cancer. High TMB tumors are thought to have a greater number of neoantigens, which can stimulate an effective immune response. Therefore, patients with high TMB tumors may be more likely to respond positively to immunotherapy.

However, not all patients with high TMB will benefit from immunotherapy; other factors such as the type and location of mutations also play a crucial role in determining treatment efficacy.

live demo · related simulation● LIVE

Why is Tumor Mutational Burden Important?

TMB assessment provides valuable information for clinicians to make informed decisions about patient care. By identifying patients with high TMB, healthcare providers can prioritize them for immunotherapy trials or treatments, potentially improving outcomes and reducing unnecessary costs associated with ineffective therapies.

Moreover, understanding TMB helps in the development of new biomarkers and therapeutic strategies that could further enhance the effectiveness of immune-based cancer treatments.

Real-World Applications

In clinical practice, TMB is used as a predictive biomarker for immunotherapy eligibility. For instance, in melanoma patients, those with high TMB are more likely to respond to checkpoint inhibitors like pembrolizumab or nivolumab. Similarly, in non-small cell lung cancer (NSCLC), high TMB has been associated with better responses to immune checkpoint inhibitors.

Research is ongoing to refine TMB measurement techniques and explore its utility across various cancer types, aiming to improve the precision of immunotherapy selection.

Frequently asked questions

How accurate are Tumor Mutational Burden tests?

Tumor mutational burden tests have high accuracy but can vary based on sequencing technology and sample quality. Advances in next-generation sequencing (NGS) technologies continue to improve the reliability of these assessments.

Can TMB be used for all types of cancer?

Currently, TMB is most commonly applied to solid tumors like melanoma, lung cancer, and colorectal cancer. However, its utility in other cancer types is being explored as research progresses.

What are the limitations of using Tumor Mutational Burden for immunotherapy?

TMB does not account for the functional impact of mutations or their location within genes. Additionally, some patients with high TMB may still have poor responses to immunotherapy due to other factors such as tumor microenvironment and immune system status.

Is there a threshold for Tumor Mutational Burden that determines eligibility?

While specific thresholds vary by cancer type, generally, tumors with a TMB of at least 10 mutations per megabase (mut/Mb) are considered high. However, the clinical significance can be context-dependent and may require further evaluation.

Try it live

Everything above runs in your browser — open Tumor Mutational Burden Immunotherapy Eligibility Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.

▶ Open Tumor Mutational Burden Immunotherapy Eligibility Simulator simulation